{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:53:47Z","timestamp":1782824027106,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.vaccine.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T04:42:11Z","timestamp":1657082531000},"page":"4676-4681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters"],"prefix":"10.1016","volume":"40","author":[{"given":"Rik L.","family":"de Swart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav S.","family":"de Leeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Oreshkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora M.","family":"Gerhards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina C.","family":"Albulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riks","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.M.","family":"van Kuppeveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Soema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berend-Jan","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben P.H.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2022.07.005_b0005","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1099\/jgv.0.001328","article-title":"ICTV virus taxonomy profile: paramyxoviridae","volume":"100","author":"Rima","year":"2019","journal-title":"J Gen Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.07.005_b0010","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/JVI.73.6.5001-5009.1999","article-title":"Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence","volume":"73","author":"Peeters","year":"1999","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.005_b0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/v12040451","article-title":"Exploring the prospects of engineered newcastle disease virus in modern vaccinology","volume":"12","author":"Bello","year":"2020","journal-title":"Viruses"},{"issue":"23","key":"10.1016\/j.vaccine.2022.07.005_b0020","doi-asserted-by":"crossref","first-page":"9788","DOI":"10.1073\/pnas.0703584104","article-title":"Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens","volume":"104","author":"DiNapoli","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.vaccine.2022.07.005_b0025","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/vaccines9111335","article-title":"Process development for newcastle disease virus-vectored vaccines in serum-free vero cell suspension cultures","volume":"9","author":"Fulber","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"10.1016\/j.vaccine.2022.07.005_b0030","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.vaccine.2010.01.001","article-title":"Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus","volume":"28","author":"Kortekaas","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.005_b0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.005_b0040","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1128\/JVI.80.3.1302-1310.2006","article-title":"Important role for the transmembrane domain of severe acute respiratory syndrome coronavirus spike protein during entry","volume":"80","author":"Broer","year":"2006","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.07.005_b0045","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1099\/0022-1317-77-5-963","article-title":"Expression of bacteriophage T7 RNA polymerase in avian and mammalian cells by a recombinant fowlpox virus","volume":"77","author":"Britton","year":"1996","journal-title":"J Gen Virol"},{"issue":"7815","key":"10.1016\/j.vaccine.2022.07.005_b0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.005_b0055","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3390\/pathogens10070824","article-title":"Predictive value of precision-cut lung slices for the susceptibility of three animal species for SARS-CoV-2 and validation in a refined hamster model","volume":"10","author":"Gerhards","year":"2021","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.005_b0060","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2022.07.005_b0065","doi-asserted-by":"crossref","first-page":"103132","DOI":"10.1016\/j.ebiom.2020.103132","article-title":"Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate","volume":"62","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.005_b0070","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/vaccines8040771","article-title":"A Newcastle disease virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine","volume":"8","author":"Sun","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.005_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26499-y","article-title":"A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.005_b0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/vaccines9020073","article-title":"Newcastle disease virus-like particles displaying prefusion-stabilized SARS-CoV-2 spikes elicit potent neutralizing responses","volume":"9","author":"Yang","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"10.1016\/j.vaccine.2022.07.005_b0085","doi-asserted-by":"crossref","first-page":"102941","DOI":"10.1016\/j.isci.2021.102941","article-title":"Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2","volume":"24","author":"Park","year":"2021","journal-title":"iScience"},{"issue":"11","key":"10.1016\/j.vaccine.2022.07.005_b0090","doi-asserted-by":"crossref","first-page":"103219","DOI":"10.1016\/j.isci.2021.103219","article-title":"Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease","volume":"24","author":"Warner","year":"2021","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.005_b0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vaccine.2010.10.024","article-title":"Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response","volume":"29","author":"DiNapoli","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.07.005_b0100","doi-asserted-by":"crossref","unstructured":"Ponce-de-Leon S, Torres M, Soto-Ramirez LE, Jose Calva J, Santillan-Doherty P, Carranza-Salazar DE, et al. Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico. medRxiv. 2022. DOI: 10.1101\/2022.02.08.22270676.","DOI":"10.1101\/2022.02.08.22270676"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:14:33Z","timestamp":1759403673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22008568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":20,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0264410X22008568"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}